ストックスクリーナーアプリを入手
0.2273
1.73%
-0.004
アフターアワーズ：
.22
-0.0073
-3.21%
前日終値:
$0.2313
開ける：
$0.23
24時間の取引高:
123.93K
Relative Volume:
1.27
時価総額：
$6.45M
収益：
-
当期純損益:
$-7.24M
株価収益率:
-0.89
EPS:
-0.2554
ネットキャッシュフロー:
$-11.29M
1週間 パフォーマンス:
-14.29%
1か月 パフォーマンス:
-24.98%
6か月 パフォーマンス:
-38.05%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.225
$0.2858
1週間の範囲:
$0.225
$0.2897
52週間の値動き範囲:
$0.225
$9.1796
Curanex Pharmaceuticals Inc Stock (CURX) Company Profile
Compare CURX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CURX
Curanex Pharmaceuticals Inc
|
0.2273 | 6.56M | 0 | -7.24M | -11.29M | -0.2554 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Curanex Pharmaceuticals Inc (CURX) 最新ニュース
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Form DEF 14C Curanex Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com Nigeria
Curanex (CURX) OKs 5.7M-share incentive plan and 1:10–1:50 reverse split - Stock Titan
Enterprise value to EBITDA forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Price to book forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Price to sales forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Enterprise value to revenue forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Curanex Pharmaceuticals Inc (CURX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Curanex Pharmaceuticals Inc (CURX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Number of shareholders of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Curanex Pharmaceuticals (NASDAQ: CURX) approves 5.7M‑share plan and 1:10–1:50 reverse split - Stock Titan
Curanex Pharmaceuticals Inc (CURX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Curanex Pharmaceuticals Inc (CURX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Curanex Pharmaceuticals Inc (CURX) Institutional Confidence - TradingKey
Curanex Pharmaceuticals Inc (CURX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Curanex Pharmaceuticals Inc (CURX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Curanex Pharmaceuticals Inc (CURX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Curanex Pharmaceuticals Inc - TradingKey
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
PMCB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Curanex Stock Sinks Toward 31 Cents as Nasdaq Clock Ticks - Bez Kabli
Curanex Pharmaceuticals Inc (CURX) Sees Modest Gain as Shares Test Key LevelsTechnical Analysis Picks - The Legal Advocate
CURXCuranex Pharmaceuticals Inc Stock Price and Quote - Finviz
Curanex Pharmaceuticals Inc. Faces Investigation Over Securities Fraud - GuruFocus
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) - Weekly Voice
Investigation launched into potential securities fraud at Curanex Pharmaceuticals after volatile stock plunge. - Pluang
Curanex Pharmaceuticals Inc. Q1 2026 10-Q Report: Financials, Growth Strategy & Pipeline Expansion - minichart.com.sg
Curanex completes manufacturing, toxicology work for ulcerative colitis drug - Investing.com UK
Curanex completes manufacturing, toxicology work for ulcerative colitis drug By Investing.com - Investing.com South Africa
CURX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Curanex Advances Phyto-N Program and Expands Indications - TipRanks
Curanex Pharmaceuticals Advances Phyto-N Toward FDA Submission for Ulcerative Colitis and Expands Pipeline to Cancer Cachexia - Minichart
Curanex Pharmaceuticals advancing phyto-n toward a planned investigational new drug submission to FDA for ulcerative colitis in Q4 2026 - marketscreener.com
Curanex (Nasdaq: CURX) advances Phyto-N toward Q4 2026 IND and adds cancer cachexia - Stock Titan
Curanex Pharmaceuticals Advances Toward Q4 2026 IND Submission for Ulcerative Colitis and Expands Pipeline to Include Cancer Cachexia - Quiver Quantitative
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission - The Manila Times
Curanex Pharmaceuticals Inc 1Q 2026: Net income $(3.15M), EPS $(0.11) — 10-Q Summary - TradingView
Curanex (NASDAQ: CURX) ramps Phyto-N R&D as Nasdaq listing faces bid-price deadline - Stock Titan
Colitis drug edges toward FDA review as Curanex targets cancer wasting - Stock Titan
TradingKey - TradingKey
Curanex awaits quarterly results as investors monitor for potential updates, CURX shares steady in quiet trading session.Investment Signal Network - newser.com
Is Curanex (CURX) a once in a decade opportunity? (Volatility Increases) 2026-05-08Stock News - newser.com
Curanex Pharmaceuticals receives extension from Nasdaq to regain bid price compliance - Investing.com Nigeria
Curanex Granted Nasdaq Extension to Regain Listing Compliance - TipRanks
Curanex Pharmaceuticals given second Nasdaq bid-price compliance period through Nov. 2, 2026 - TradingView
[8-K] Curanex Pharmaceuticals Inc Reports Material Event - Stock Titan
Get insights into the top gainers and losers of Tuesday's after-hours session. - ChartMill
CURX Investors Have Opportunity to Join Curanex Pharmaceuticals Inc Fraud Investigation with ... - Caledonian Record
CURX Investors Have Opportunity to Join Curanex Pharmaceuticals Inc Fraud Investigation with the Schall Law Firm - GlobeNewswire
CURX Ownership | CURANEX PHARMACEUTICALS INC (NASDAQ:CURX) - ChartMill
Curanex Pharmaceuticals Inc (CURX) 財務データ
収益
当期純利益
現金流量
EPS
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):